Replimune's shares crater as FDA rejects melanoma drug

Replimune's shares plummeted 76% after the FDA issued a Complete Response Letter for its melanoma drug candidate RP1, citing the Phase 1/2 Ignyte trial's heterogeneous patient population and issues with the confirmatory study design. The company, which held $483.8 million in cash as of March, expressed surprise at the FDA's concerns given prior agency discussions and stated that without timely accelerated approval, RP1's development is not viable, signaling a significant setback for the program.

Analysis

The U.S. Food and Drug Administration's issuance of a Complete Response Letter (CRL) for Replimune's melanoma drug candidate, RP1, represents a significant clinical and regulatory setback, as evidenced by the immediate 76% collapse in the company's share price. The FDA's rejection was rooted in fundamental critiques of the pivotal Phase 1/2 Ignyte trial, which it deemed an inadequate and poorly controlled investigation due to the heterogeneity of the patient population. This criticism directly contradicts the company's prior statements, where CEO Sushil Patel indicated the broad study design was informed by FDA guidance to capture a 'real-world population.' This disconnect raises serious questions about communication and alignment between Replimune and the regulatory agency. The CRL also flagged issues with the design of the necessary Phase 3 confirmatory trial. The financial implications are severe; management has stated that without timely accelerated approval, the RP1 program is 'not viable.' While the company holds a solid cash position of $483.8 million as of March, the unexpected rejection invalidates the near-term commercial thesis and introduces a prolonged, costly, and uncertain path forward, jeopardizing the program's survival.

Key Decisions for Investors

• The primary investment thesis for Replimune has been invalidated by the FDA's rejection, making the stock's near-term outlook highly speculative and dependent on a successful, but uncertain, renegotiation of the clinical pathway for RP1.
• Investors should shift focus to the company's cash runway of $483.8 million against its burn rate, as management's statement that the program is 'not viable' without timely approval signals a high risk of capital depletion or strategic pivots.
• It is prudent to await clarity from the planned meeting between Replimune and the FDA before making any investment decisions, as the outcome will determine if a viable, albeit significantly delayed, path to approval exists.